Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Lawyers lose in better deal for pelvic mesh victims

A law firm that ran two class actions for women harmed by pelvic mesh implants will lose out on a $38.5 million cut of $405 million in settlement funds.

AAP

This J&J exec sold Tylenol and Listerine. Now she runs its $27B medtech business

Ashley McEvoy pivoted from over-the-counter products to medical devices.

Fortune

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Fake Sudafed Is Bullshit, Just As You Suspected

Legal restrictions on pseudoephedrine have not reduced meth use, but they have driven people with colds or allergies toward substitutes that seem to be completely ineffective.

Reason

The FDA asked advisers to take another look at phenylephrine, which became the main drug in over-the-counter decongestants when medicines with an older ingredient were moved behind pharmacy counters.

WEKU

Advisers to the Food and Drug Administration voted unanimously on Tuesday against the effectiveness of the key drug phenylephrine found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.

Chicago Sun-Times

Government advisers say the leading decongestant used by millions of Americans to treat nasal congestion doesn't actually work

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value

An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders.

Barchart

About the new drug pricing negotiations

The first eligible drugs treat diabetes, blood clots, blood cancers, arthritis and heart disease

Salon

5 things consumers need to know about Medicare’s new drug-pricing negotiations, how they’ll affect you

This could help people whose Medicare drug plans require big copayments. But the main relief will come from part of the Inflation Reduction Act that caps drug spending by Medicare recipients at $2,000 a year starting in 2025.

Chicago Sun-Times

Cost of tuberculosis treatment halved in deal to permit generic versions

Johnson & Johnson’s year-long deal on life-saving drug bedaquiline is seen as critical move in campaign against disease

The Guardian - UK

Is Johnson & Johnson (JNJ) a Buy Before September Begins?

Pharma giant Johnson & Johnson (JNJ) has posted robust second-quarter results and raised its full-year outlook. Should investors look into the stock before September begins? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

Kenvue Joins S&P 500 on Friday: Time to Buy?

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Barchart

'Private Tyranny' Is Less Private Than You Think

Sohrab Ahmari inadvertently gives even more reasons to reduce the power of the state.

Reason

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Newly released FBI tapes show suspect suggesting how Tylenol murders were carried out

In the 2008 footage James Lewis is seen going into detail about how the Tylenol killer would have carried out the poisonings

StockNews.com

Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock?

Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading….

Investors Business Daily

S&P 500: Entertainment Giants, AI Play Lead Monday's 5 Best; Medtech Firms Sicken

Paramount and Disney, along with AI play Adobe, led the S&P 500. Dexcom and several medical products firms struggled.

The Street

Stocks Mixed, Jobs Data On Deck, Johnson & Johnson, Walmart, Yellow

Stock futures mixed amid 'soft landing' hopes for U.S. economy; Week Ahead: jobs data in focus, earnings reports accelerate; Johnson & Johnson slides as talc bankruptcy plan rejected by judge; Walmart buys out Tiger Global, expands Flipkart stake and Yellow slides as Teamsters say trucking giant preparing for bankruptcy.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

Investors Business Daily

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review

The Dow Jones lead the market rally, while Tesla, Netflix and Taiwan Semiconductor hit growth stocks Thursday.

The Street

Johnson & Johnson Stock Just Got A Surprising New Price Target

Here's what may happen to J&J's shares next.

Investors Business Daily

J&J Stock Roars Higher, Retaking Its 200-Day Line As Small Drugs Drive Big Beat

Johnson & Johnson beat quarterly expectations Thursday, helped by its new cancer drug Carvykti, and JNJ stock surged.

The Street

Johnson & Johnson Earnings Top Forecasts On Solid Medical Device Sales

“We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation," said CEO Joaquin Duato.

The Street

Stocks Mixed, Tesla, Netflix, Johnson & Johnson, United Airlines

Stock futures mixed as tech sector outlooks dim; Tesla shares slide as Elon Musk signals more EV price cuts; Netflix slumps as blowout subscriber numbers can't offset revenue miss; Johnson & Johnson earnings on deck following Kenvue spin-off and United Airlines shares higher after solid Q2 earnings, outlook lift.

The Hindu

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India

MSF reiterated its call for Johnson & Johnson to publicly announce that it will not enforce any ‘secondary’ patents for bedaquiline in any country with a high burden of TB, as J&J’s 20-year primary patent on bedaquiline expired on July 18.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.